Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection
- L. E., Weimer
- V., Fragola
- M., Floridia
- Guaraldi, Giovanni
- N., Ladisa
- D., Francisci
- R., Bellagamba
- A., Degli Antoni
- G., Parruti
- A., Giacometti
- P. E., Manconi
- A., Vivarelli
- G., D'Ettorre
- M. S., Mura
- S., Cicalini
- R., Preziosi
- L., Sighinolfi
- G., Verucchi
- R., Libertone
- M., Tavio
- L., Sarmati
- R., Bucciardini
DOIAbstract
OBJECTIVES: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. METHODS: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. RESULTS: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA...
Add to ORKG